Dr. Rini on Sequencing of Immunotherapy Combinations in RCC

Brian I. Rini, MD,
Published: Thursday, Jul 20, 2017



Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).

According to Rini, not all of the combinations are going to be getting the same amount of use, causing competition between the combination regimens.

Sequencing of these agents is still a remaining question that needs further trials to investigate, explains Rini.



Brian I. Rini, MD, professor of Medicine, Cleveland Clinic, discusses sequencing of immunotherapy combinations for patients with renal cell carcinoma (RCC).

According to Rini, not all of the combinations are going to be getting the same amount of use, causing competition between the combination regimens.

Sequencing of these agents is still a remaining question that needs further trials to investigate, explains Rini.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x